PTCT Overview

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Wall Street analysts forecast PTCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTCT is78.18 USD with a low forecast of 54.00 USD and a high forecast of 118.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

PTC Therapeutics Inc revenue for the last quarter amounts to 164.68M USD, decreased -22.75

PTC Therapeutics Inc. EPS for the last quarter amounts to -1.64 USD, increased 92.94

PTC Therapeutics Inc (PTCT) has 991 emplpoyees as of March 12 2026.

Today PTCT has the market capitalization of 5.44B USD.